VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CHE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CHEChemed Corporation
$546.75$7.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCHEFinancials

Chemed Corporation (CHE) Income Statement

30Y historyFree accessUpdated daily

Revenue growth reaccelerated to 10.6% year-over-year in Q3 2026 with gross margin recovering to 33.7% from a 28.9% trough, though margins remain 290 basis points below the 36.6% Q4 2024 peak as labor costs and reimbursement mix continue to pressure profitability.

Income StatementBalance SheetCash FlowRatios

CHE Income Statement

Annual statement

CHE Income Statement

Chemed Corporation (CHE) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue2.66B2.53B2.43B2.26B2.13B2.14B2.08B1.94B1.78B1.67B1.58B1.54B1.46B1.41B1.43B1.36B1.28B1.19B1.15B1.1B1.02B915.97M734.88M260.78M253.69M337.91M355.31M453.6M381.3M341.7M301.2M
Revenue Growth %5.15%4.06%7.37%6.06%-0.2%2.87%7.27%8.75%6.96%5.7%2.17%5.98%3.04%-1.17%5.46%5.89%7.59%3.59%4.44%8%11.2%24.64%181.8%2.79%-24.92%-4.9%-21.67%18.96%11.59%13.45%-56.92%
Cost of Goods Sold1.82B1.77B1.58B1.47B1.37B1.37B1.38B1.32B1.23B1.15B1.12B1.09B1.03B1.01B1.03B970.48M906.02M834.57M810.55M767.07M730.12M644.48M506.77M146.82M140.95M205.62M208.98M269.8M230.5M206M178.4M
COGS % of Revenue-70.03%64.86%64.72%64.16%64.02%66.27%68.15%68.87%69.03%70.74%70.47%71.05%71.38%72.26%71.57%70.75%70.12%70.55%69.73%71.68%70.36%68.96%56.3%55.56%60.85%58.82%59.48%60.45%60.29%59.23%
Gross Profit842.25M758.34M854.35M798.82M765.09M769.8M701.39M617.43M555M516.19M461.45M455.78M421.61M404.52M396.72M385.49M374.53M355.66M338.39M332.99M288.46M271.49M228.11M113.96M112.74M132.29M146.33M183.8M150.8M135.7M122.8M
Gross Margin %31.65%29.97%35.14%35.28%35.84%35.98%33.73%31.85%31.13%30.97%29.26%29.53%28.95%28.62%27.74%28.43%29.25%29.88%29.45%30.27%28.32%29.64%31.04%43.7%44.44%39.15%41.18%40.52%39.55%39.71%40.77%
Gross Profit Growth %--11.24%6.95%4.41%-0.61%9.75%13.6%11.25%7.52%11.86%1.24%8.1%4.22%1.97%2.91%2.93%5.3%5.1%1.62%15.44%6.25%19.02%100.17%1.08%-14.78%-9.59%-20.39%21.88%11.13%10.5%-49.21%
Operating Expenses471.57M417.19M487.86M458.25M421.59M426.76M311.71M360.05M311.37M403.16M282.7M271.32M253.19M271.13M240.3M231.76M231.01M229.32M205.54M210.24M183.49M194.72M170.15M105.18M95.6M141.07M116.84M157M130.7M116.1M105.4M
OpEx % of Revenue-16.49%20.07%20.24%19.75%19.95%14.99%18.57%17.47%24.19%17.93%17.58%17.39%19.18%16.8%17.09%18.04%19.27%17.89%19.11%18.01%21.26%23.15%40.34%37.68%41.75%32.88%34.61%34.28%33.98%34.99%
Selling, General & Admin446.5M417.19M424.36M395.12M358.73M366.73M330.22M305.71M271.21M276.65M248.06M237.82M222.59M215.56M208.66M202.26M201.96M197.43M175.33M184.06M161.18M157.26M147.06M95.36M85.02M104.72M103.46M136.9M113.4M100.9M93.6M
SG&A % of Revenue-16.49%17.45%17.45%16.8%17.14%15.88%15.77%15.21%16.6%15.73%15.41%15.28%15.25%14.59%14.92%15.77%16.59%15.26%16.73%15.82%17.17%20.01%36.57%33.52%30.99%29.12%30.18%29.74%29.53%31.08%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses1000K063.49M63.13M62.86M60.04M-18.51M54.34M40.16M126.5M34.64M33.5M30.6M55.56M31.65M29.5M29.04M31.89M30.2M26.18M22.3M37.46M23.09M9.82M10.58M36.34M13.37M20.1M17.3M15.2M11.8M
Operating Income370.86M338.25M366.49M340.57M343.5M343.04M389.68M257.38M243.63M113.03M178.75M184.46M168.42M133.39M156.42M153.73M143.52M126.34M132.86M122.75M104.98M79.38M58.11M-7.72M-1.55M18.82M33.47M26.8M20.1M19.6M31.3M
Operating Margin %13.94%13.37%15.07%15.04%16.09%16.04%18.74%13.28%13.67%6.78%11.34%11.95%11.56%9.44%10.94%11.34%11.21%10.62%11.56%11.16%10.31%8.67%7.91%-2.96%-0.61%5.57%9.42%5.91%5.27%5.74%10.39%
Operating Income Growth %--7.71%7.61%-0.85%0.13%-11.97%51.4%5.64%115.54%-36.76%-3.09%9.52%26.26%-14.72%1.75%7.11%13.6%-4.9%8.23%16.93%32.24%36.62%852.67%-398.06%-108.24%-43.77%24.88%33.33%2.55%-37.38%-5.15%
EBITDA438.45M403.09M429.54M401.43M402.67M402.09M446.26M302.58M282.5M148.66M213.39M217.96M199.02M162.74M186.94M183.23M172.56M154.25M160.36M148.14M128.78M102.29M78.29M2.1M9.03M40.09M56.91M46.9M37.4M34.8M43.1M
EBITDA Margin %16.48%15.93%17.67%17.73%18.86%18.8%21.46%15.61%15.85%8.92%13.53%14.12%13.67%11.51%13.07%13.51%13.48%12.96%13.96%13.47%12.64%11.17%10.65%0.81%3.56%11.87%16.02%10.34%9.81%10.18%14.31%
EBITDA Growth %5.44%-6.16%7%-0.31%0.14%-9.9%47.48%7.11%90.03%-30.33%-2.1%9.52%22.3%-12.95%2.03%6.18%11.88%-3.81%8.25%15.03%25.9%30.66%3626.23%-76.72%-77.49%-29.55%21.35%25.4%7.47%-19.26%-15.82%
D&A (Non-Cash Add-back)67.59M64.84M63.05M60.87M59.17M59.05M56.58M45.2M38.86M35.63M34.64M33.5M30.6M29.34M30.52M29.5M29.04M27.9M27.5M25.39M23.8M22.91M20.18M9.82M10.58M21.27M23.45M20.1M17.3M15.2M11.8M
EBIT378.55M357.53M401.25M353.48M334.26M352.18M398.35M266.14M244.59M121.19M180.77M183.77M170.97M138.86M160.54M154.44M145.79M132.22M127.53M113.08M104.98M76.77M57.95M8.77M17.14M15.96M29.49M26.8M20.1M19.6M17.4M
Net Interest Income-1.96M7M12.83M3.16M-4.23M-1.49M-1.6M-4.02M-4.32M-3.85M-3.33M-3.36M-8.21M-14.19M-13.91M-13.46M-11.52M-11.18M-11.38M-7.94M00000000000
Interest Income2.96M8.74M14.61M6.27M355K377K757K513K671K427K383K281K0847K809K426K444K423K743K3.3M00000000000
Interest Expense4.92M1.75M1.78M3.11M4.58M1.87M2.35M4.54M4.99M4.27M3.71M3.65M8.21M15.04M14.72M13.89M11.96M11.6M5.99M11.24M00000000000
Other Income/Expense11.46M17.53M32.97M9.8M-13.82M7.28M6.31M4.23M-4.03M3.88M-1.7M-4.33M-5.67M-9.56M-12.94M-13.17M-9.69M-5.72M-10.51M-20.92M-14.7M-24.73M-21.02M7.67M-18.42M-29.14M-2.54M4.2M12M8.3M11M
Pretax Income382.32M355.78M399.46M350.37M329.68M350.31M395.99M261.61M239.6M116.92M177.05M180.13M162.75M123.83M145.82M140.56M133.83M120.62M122.34M101.84M90.28M57.28M37.09M1.25M-1.27M-10.06M33.25M31M32.1M27.9M53.6M
Pretax Margin %14.37%14.06%16.43%15.47%15.44%16.38%19.04%13.5%13.44%7.01%11.23%11.67%11.18%8.76%10.2%10.37%10.45%10.13%10.65%9.26%8.86%6.25%5.05%0.48%-0.5%-2.98%9.36%6.83%8.42%8.17%17.8%
Income Tax99.92M90.54M97.47M77.86M80.06M81.76M76.52M41.69M34.06M18.74M68.31M69.85M63.44M46.6M56.52M54.58M52M46.58M50.24M39.06M32.56M19.58M13.8M4.75M6.85M-3.36M12.66M11.3M12.2M10.8M21.9M
Effective Tax Rate %26.13%25.45%24.4%22.22%24.28%23.34%19.32%15.93%14.21%16.03%38.58%38.78%38.98%37.63%38.76%38.83%38.85%38.62%41.06%38.36%36.07%34.18%37.2%379.92%-537.02%33.41%38.09%36.45%38.01%38.71%40.86%
Net Income282.4M265.24M302M272.51M249.62M268.55M319.47M219.92M205.54M98.18M108.74M110.27M99.32M77.23M89.3M85.98M81.83M73.78M71.02M63.98M50.65M35.82M27.51M-3.44M-1.81M-10.38M20.58M19.7M19.9M30.3M32.3M
Net Margin %10.61%10.48%12.42%12.03%11.69%12.55%15.36%11.34%11.53%5.89%6.9%7.14%6.82%5.46%6.24%6.34%6.39%6.2%6.18%5.82%4.97%3.91%3.74%-1.32%-0.71%-3.07%5.79%4.34%5.22%8.87%10.72%
Net Income Growth %1.29%-12.17%10.82%9.17%-7.05%-15.94%45.26%7%109.36%-9.72%-1.39%11.03%28.6%-13.52%3.87%5.07%10.91%3.9%11.01%26.31%41.42%30.19%900.93%-89.46%82.53%-150.4%4.49%-1%-34.32%-6.19%39.83%
Net Income (Continuing)282.4M265.24M302M272.51M249.62M268.55M319.47M219.92M205.54M98.18M108.74M110.27M99.32M77.23M89.3M85.98M81.83M74.04M72.11M62.77M57.72M36.23M19.09M11.19M11.11M-10.74M18.64M19.7M19.9M17.1M25.1M
Discontinued Operations00000000000000000000008.33M00000000
Minority Interest00000000000000000000000000000010.8M
EPS (Diluted)21.5018.4219.8917.9316.5316.8519.4813.3112.235.866.486.335.574.164.624.103.553.243.042.551.901.361.12-0.17-0.09-0.531.000.930.991.511.63
EPS Growth %10.58%-7.39%10.93%8.47%-1.9%-13.5%46.36%8.83%108.7%-9.57%2.37%13.64%33.89%-9.96%12.68%15.49%9.57%6.58%19.22%34.21%39.71%21.43%758.82%-85.39%82.7%-153%7.53%-6.06%-34.44%-7.36%38.14%
EPS (Basic)-18.4220.1018.1116.7217.1420.0213.7712.806.116.646.545.794.244.724.193.623.293.082.611.941.401.14-0.17-0.09-0.531.010.930.991.521.65
Diluted Shares Outstanding13.13M14.4M15.19M15.2M15.1M15.94M16.4M16.53M16.8M16.74M16.79M17.42M17.84M18.59M19.34M20.95M23.03M22.74M23.37M25.08M26.67M26.3M24.64M19.91M19.77M19.43M19.85M21.03M20.2M20.03M19.82M
Basic Shares Outstanding13.06M14.4M15.02M15.05M14.93M15.67M15.96M15.97M16.06M16.06M16.38M16.87M17.16M18.2M18.92M20.52M22.59M22.45M23.06M24.52M26.12M25.55M24.12M19.85M19.72M19.43M19.67M20.94M20.12M19.88M19.58M
Dividend Payout Ratio-11.95%8.97%8.62%8.82%8.2%6.6%9%9.08%17.69%15.12%14.15%14.35%18.32%14.59%14.58%14.52%11.06%7.81%9.2%12.48%17.23%20.78%---19.54%114.21%109.05%69.31%63.16%

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetFortress
Cash FlowStable
Top Statement Risk

Labor inflation vs. reimbursement caps

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Growth Reaccelerates After Mid-Cycle Pause

According to Chemed's quarterly income statements, revenue growth rebounded to 10.6% year-over-year in Q3 2026, up from just 1.6% in Q1 2026, suggesting the mid-2025 deceleration proved transitory as sequential revenue climbed from $618.8M to $690.9M over five quarters.

The YoY growth trajectory reveals a pronounced V-shaped pattern: near-zero growth in Q4 2025 (-0.1%) and Q1 2026 (1.6%) bracketed a recovery to high-single-digit rates in the most recent two quarters. This volatility likely reflects a combination of base effects from a strong Q1 2025 comparison and potential timing dynamics in VITAS patient admissions, alongside Roto-Rooter's weather-dependent seasonal demand. Investors should monitor whether the current growth rate of 8–10% proves sustainable or whether the mid-cycle pause presages renewed deceleration once favorable comparisons normalize.

Gross Margin Recovery Masks Structural Cost Pressures

As reported in Chemed's financial statements, gross margins contracted from a peak of 36.6% in Q4 2024 to a trough of 28.9% in Q3 2025 before recovering to 33.7% in Q3 2026, reflecting meaningful margin volatility driven by labor costs and reimbursement mix.

The 770 basis point swing from peak to trough within approximately three quarters is unusually wide for a business with a large recurring revenue base, suggesting that external cost pressures — particularly wage inflation in hospice staffing and technician compensation at Roto-Rooter — have materially impacted the cost of revenue line. While Q3 2026's recovery to 33.7% is encouraging, margins remain roughly 290 basis points below the Q4 2024 peak, indicating the recovery may be incomplete. The persistent gap between current and peak margins suggests that Medicare reimbursement constraints and ongoing healthcare labor tightness may be establishing a structurally lower margin ceiling than historically observed.

SG&A Discipline Supports Operating Leverage Recovery

Based on Chemed's reported figures, SG&A spending held broadly flat at $99.6M to $115.2M across ten quarters while revenue expanded from $595.9M to $690.9M, indicating overhead leverage as SG&A declined from roughly 16.7% of revenue to 16.1% in Q3 2026.

The relatively contained SG&A trajectory — rising only modestly even as revenue grew nearly 16% over the period — suggests management has maintained tight control over corporate overhead, which is consistent with the company's historical capital allocation discipline. Operating margins nonetheless swung from 17.8% in Q4 2024 to 11.0% in Q2 2025 before recovering to 14.0% in Q3 2026, implying that the operating margin compression was driven primarily by gross profit dynamics rather than overhead bloat. This distinction matters: if SG&A leverage is genuinely structural, then any further gross margin recovery should translate disproportionately into operating income expansion.

SBC Volatility Obscures Earnings Trajectory

As disclosed in Chemed's quarterly filings, stock-based compensation has exhibited unusual volatility, swinging from -$15.2M in Q3 2025 to $23.5M in Q4 2025, creating significant noise in net income and complicating any assessment of underlying operational earnings quality across reporting periods.

The erratic SBC figures — ranging from -$15.2M to $23.5M — introduce substantial quarter-to-quarter distortion in net income comparisons, making it difficult to isolate true operating performance from compensation-related accounting adjustments. For instance, Q4 2025's $76.8M net income was earned alongside $23.5M of SBC, while Q3 2026's $71.6M net income reflected a -$3.7M SBC charge, suggesting that adjusted earnings on a consistent basis may tell a different story than headline EPS. Analysts should consider normalizing for SBC when evaluating the durability of the reported EPS recovery from $4.46 in Q3 2025 to $5.49 in Q3 2026, as the underlying operational trajectory may be smoother than headline numbers suggest.

Margin Recovery Faces Structural Reimbursement Ceiling

Despite the recent gross margin recovery to 33.7% in Q3 2026, Chemed's margins remain 290 basis points below the Q4 2024 peak, and persistent healthcare labor inflation combined with Medicare per-diem rate constraints may permanently limit the company's ability to recapture prior profitability levels.

The most compelling bear case centers on the observation that each sequential margin recovery since mid-2025 has failed to reach the prior cycle's high — 33.5% in Q1 2025 versus 36.6% in Q4 2024, and 33.7% in Q3 2026 versus 34.6% in Q2 2024 — suggesting a potentially declining margin ceiling consistent with structural cost absorption challenges in VITAS's labor-intensive model. Additionally, the Q3 2026 EPS of $5.49, while encouraging, still fell short of Q4 2024's $6.02, raising the question of whether the recent re-acceleration in revenue growth is being fully captured at the earnings line or partially offset by a permanently elevated cost base that warrants closer scrutiny in subsequent filings.

CHE — Frequently Asked Questions

Quick answers to the most common questions about buying CHE stock.

What was Chemed Corporation's (CHE) revenue in 2025?

For fiscal year 2025, Chemed Corporation (CHE) reported total revenue of $2.53B. This represents a 740.0% increase compared to $301.2M in 1996.

Is Chemed Corporation (CHE) profitable?

Chemed Corporation (CHE) is profitable, generating $265.2M in net income for the fiscal year ending 2025 with a net profit margin of 10.5%.

What is Chemed Corporation's operating profit margin?

Chemed Corporation (CHE) reported an operating income of $338.2M, resulting in an operating profit margin of 13.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Chemed Corporation's gross profit and gross margin?

Chemed Corporation (CHE) generated $758.3M in gross profit for the year, representing a gross profit margin of 30.0%. This demonstrates the company's core pricing power and production efficiency.